DBV TECHNOLOGIE/S (NASDAQ:DBVT) and Tcr2 Therapeutics (NASDAQ:TCRR) Financial Contrast

DBV TECHNOLOGIE/S (NASDAQ:DBVT) and Tcr2 Therapeutics (NASDAQ:TCRR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for DBV TECHNOLOGIE/S and Tcr2 Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV TECHNOLOGIE/S 1 4 5 0 2.40
Tcr2 Therapeutics 0 1 6 0 2.86

DBV TECHNOLOGIE/S currently has a consensus target price of $13.18, suggesting a potential upside of 71.60%. Tcr2 Therapeutics has a consensus target price of $26.33, suggesting a potential upside of 72.00%. Given Tcr2 Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Tcr2 Therapeutics is more favorable than DBV TECHNOLOGIE/S.

Valuation and Earnings

This table compares DBV TECHNOLOGIE/S and Tcr2 Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DBV TECHNOLOGIE/S $17.17 million 40.83 -$196.14 million ($3.39) -2.27
Tcr2 Therapeutics N/A N/A -$24.25 million ($98.53) -0.16

Tcr2 Therapeutics has lower revenue, but higher earnings than DBV TECHNOLOGIE/S. DBV TECHNOLOGIE/S is trading at a lower price-to-earnings ratio than Tcr2 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DBV TECHNOLOGIE/S and Tcr2 Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DBV TECHNOLOGIE/S N/A N/A N/A
Tcr2 Therapeutics N/A -47.95% -26.77%

Institutional and Insider Ownership

51.7% of DBV TECHNOLOGIE/S shares are held by institutional investors. Comparatively, 33.4% of Tcr2 Therapeutics shares are held by institutional investors. 15.3% of DBV TECHNOLOGIE/S shares are held by company insiders. Comparatively, 39.1% of Tcr2 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Tcr2 Therapeutics beats DBV TECHNOLOGIE/S on 6 of the 11 factors compared between the two stocks.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.